The "CPC clip motif": A conserved structural signature for heparin-binding proteins

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Torrent, Marc ^a,b   Nogués, M Victòria ^a   Andreu, David ^b   Boix, Ester ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ARGININE; ASPARAGINE; CHEMOKINE; FRACTALKINE; GLUTAMINE; GLYCOSAMINOGLYCAN; HEPARIN; HEPARIN BINDING PROTEIN; LYMPHOTACTIN; LYSINE; SERINE; THREONINE; TYROSINE;

ARTICLE; CPC CLIP MOTIF; MOLECULAR DOCKING; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DATABASE; PROTEIN MOTIF; PROTEIN STRUCTURE; SEQUENCE ALIGNMENT; SIMULATION;

AMINO ACID MOTIFS; AMINO ACIDS; AMYLOID BETA-PEPTIDES; BINDING SITES; CARRIER PROTEINS; CONSERVED SEQUENCE; DATABASES, PROTEIN; HEPARIN; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; THERMODYNAMICS;

EID: 84864647179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042692     Document Type: Article

References (40)

1. Gandhi NS, Mancera RL, ((2008)) The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72: 455-482.
2. Peplow PV, ((2005)) Glycosaminoglycan: a candidate to stimulate the repair of chronic wounds. Thromb Haemost 94: 4-16.
3. Casu B, Guerrini M, Torri G, ((2004)) Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Des 10: 939-949.
4. Kovensky J, ((2009)) Sulfated oligosaccharides: new targets for drug development? Curr Med Chem 16: 2338-2344.
5. Liu D, Shriver Z, Qi Y, Venkataraman G, Sasisekharan R, ((2002)) Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin Thromb Hemost 28: 67-78.
6. Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S, ((2007)) Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14: 21-32.
7. Young E, ((2008)) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122: 743-752.
8. Rider CC, ((1997)) The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection. Glycoconj J 14: 639-642.
9. Mulloy B, Linhardt RJ, ((2001)) Order out of complexity-protein structures that interact with heparin. Curr Opin Struct Biol 11: 623-628.
10. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ, ((1998)) Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20: 156-167.
11. Raghuraman A, Mosier PD, Desai UR, ((2006)) Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s). J Med Chem 49: 3553-3562.
12. Cardin AD, Weintraub HJ, ((1989)) Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9: 21-32.
13. Capila I, Linhardt RJ, ((2002)) Heparin-protein interactions. Angew Chem Int Ed Engl 41: 391-412.
14. Fromm JR, Hileman RE, Caldwell EE, Weiler JM, Linhardt RJ, ((1997)) Pattern and spacing of basic amino acids in heparin binding sites. Arch Biochem Biophys 343: 92-100.
15. Kleywegt GJ, ((1999)) Recognition of spatial motifs in protein structures. J Mol Biol 285: 1887-1897.
16. Madsen D, Kleywegt GJ, ((2001)) Interactive motif and fold recognition in protein structures. J Appl Cryst 35: 137-139.
17. Thompson LD, Pantoliano MW, Springer BA, ((1994)) Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33: 3831-3840.
18. Bae J, Desai UR, Pervin A, Caldwell EE, Weiler JM, et al. ((1994)) Interaction of heparin with synthetic antithrombin III peptide analogues. Biochem J 301 (Pt 1): 121-129.
19. Krissinel E, Henrick K, ((2007)) Inference of macromolecular assemblies from crystalline state. J Mol Biol 372: 774-797.
20. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE, ((2005)) Regulation of protein function by glycosaminoglycans-as exemplified by chemokines. Annu Rev Biochem 74: 385-410.
21. Weber C, Koenen RR, ((2006)) Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol 27: 268-273.
22. Raman R, Sasisekharan V, Sasisekharan R, ((2005)) Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol 12: 267-277.
23. Mackay CR, ((2001)) Chemokines: immunology's high impact factors. Nat Immunol 2: 95-101.
24. Sallusto F, Baggiolini M, ((2008)) Chemokines and leukocyte traffic. Nat Immunol 9: 949-952.
25. Nomenclature IUoISWHOSoC ((2001)) Chemokine/chemokine receptor nomenclature. J Leukoc Biol 70: 465-466.
26. Shaw JP, Johnson Z, Borlat F, Zwahlen C, Kungl A, et al. ((2004)) The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure 12: 2081-2093.
27. Lau EK, Paavola CD, Johnson Z, Gaudry JP, Geretti E, et al. ((2004)) Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem 279: 22294-22305.
28. Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, et al. ((2007)) Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem 282: 10018-10027.
29. Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi S, et al. ((1998)) Identification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem 273: 16551-16554.
30. Kuloglu ES, McCaslin DR, Kitabwalla M, Pauza CD, Markley JL, et al. ((2001)) Monomeric solution structure of the prototypical 'C' chemokine lymphotactin. Biochemistry 40: 12486-12496.
31. Tuinstra RL, Peterson FC, Kutlesa S, Elgin ES, Kron MA, et al. ((2008)) Interconversion between two unrelated protein folds in the lymphotactin native state. Proc Natl Acad Sci U S A 105: 5057-5062.
32. Volkman BF, Liu TY, Peterson FC, ((2009)) Chapter 3. Lymphotactin structural dynamics. Methods Enzymol 461: 51-70.
33. Peterson FC, Elgin ES, Nelson TJ, Zhang F, Hoeger TJ, et al. ((2004)) Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem 279: 12598-12604.
34. Haskell CA, Cleary MD, Charo IF, ((1999)) Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 274: 10053-10058.
35. Hoover DM, Mizoue LS, Handel TM, Lubkowski J, ((2000)) The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement. J Biol Chem 275: 23187-23193.
36. Herrup K, ((2010)) Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 30: 16755-16762.
37. Valle-Delgado JJ, Alfonso-Prieto M, de Groot NS, Ventura S, Samitier J, et al. ((2010)) Modulation of Abeta42 fibrillogenesis by glycosaminoglycan structure. FASEB J 24: 4250-4261.
38. Ariga T, Miyatake T, Yu RK, ((2010)) Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: amyloidogenesis and therapeutic strategies-a review. J Neurosci Res 88: 2303-2315.
39. Small DH, Nurcombe V, Reed G, Clarris H, Moir R, et al. ((1994)) A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J Neurosci 14: 2117-2127.
40. Wang Y, Ha Y, ((2004)) The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol Cell 15: 343-353.